University of California USA
Dupuytren University Hospital France
University of Athens Greece
Marseille University France
Plovdiv Medical University Bulgaria
CEO and co-founder of Healthy Networks Belarus
Research Officer, Hywel Dda University Health Board UK
Pulmonologist, University of Athens Greece
Recommended Global Healthcare Management Webinars & Conferences
Sessions and Tracks
Track 01: Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide Chronic Obstructive Pulmonary Disease is a progressive disease that causes airflow blockage and problems related to breathing. It can cause coughing that produces large amounts of a slimy substance called mucus, wheezing, and shortness of breathe as well as chest tightness. Cigarette smoking is the main cause of COPD. Long-term exposure to various lung irritants such as air pollution, chemical fumes or dusts also contributes to COPD. A rare genetic situation called alpha-1 antitrypsin (AAT) deficiency can also lead to COPD. COPD cannot be cured but it can be treated to lower the chance of complications, and generally improve quality of life.
End-stage Lung Disease
Obstructive lung disease
Track 02: COPD: Sign and Symptoms
For Chronic Obstructive Pulmonary Disease there are no sign and symptoms but sometimes it may show mild symptoms. As the disease gets low, symptoms usually progress more severe. The first symptom of COPD is usually a long-term or chronic cough. If you have COPD, you also may constantly have colds or other respiratory infections such as the flu or influenza. Often do not appear until significant lung damage or lung cancer has occurred, and they usually damage over time, particularly if smoking exposure continues. Symptoms involve increasing breathlessness this may just occur when exercising at first and you may frequently wake up at night feeling breathless, a persistent chesty cough with phlegm that never seems to go away, periodic chest infections, persistent wheezing.
Shortness of breath
Unintended weight loss
Track 03: Types of COPD
People with different kinds of COPD experience difficulty in breathing and shortness of breath. The two major infections that fall under the extent of COPD are: Chronic bronchitis, which involves a long-term cough with mucus, it is a long-term inflammation of the bronchi, which results in increased exhibition of mucus, as well as other changes. These changes may result in breathing problems, frequent infections, cough, disability, anxiety and depression. Emphysema which includes harms to the lungs over time. Emphysema is a chronic lung condition in which alveoli may be destroyed, narrowed, narrowed, stretched, and over-inflated. This can cause a reduction in respiratory volume and breathlessness. Harm to the air sacs is irreversible and brings about permanent "holes" in the lung tissue.
Track 04: Drug Discovery of COPD
Chronic obstructive pulmonary disease is an expanding worldwide medical issue and cause of death. COPD mostly influencing small airway routes and lung parenchyma that prompts dynamic aviation route deterrent. COPD is a standout amongst the most widely recognized infections on the globe, and there is a global increase in generality, however there are no drugs available at present that halt the relentless progression of this disease. In any case, a superior perception of the cell and molecular mechanisms that are associated with the underlying inflammatory and destructive processes has uncovered a few new centres for which drugs are presently being developed, and the prospects for detection new medications are good.
Track 05: Effect of COVID-19 on Lungs
COVID-19 is a respiratory disease which causes a range of breathing issues, from mild to critical. Older adults and people who have other health conditions like heart disease, cancer and diabetes may have more significant symptoms when compared to others. Coronavirus can infect the upper or lower part of the respiratory zone and travels down the airways making the edge become irritated and inflamed. In some instances, the infection can reach all the way down into the alveoli. Respiratory inflammation can be notice on a chest X-ray or CT scan. Contemporary, convalescent plasma from a recovered patient is given by transfusion to a patient who is suffering from COVID-19. The donor antibodies may help the patient fight the illness, possibly shortening the reducing the severity of the disease
Track 06: Diagnosis and Treatment of COPD
The major test for diagnosing COPD is a lung function test is known as spirometer which involves the use of a machine called a spirometer that measures how much air you are able to move by taking a deep breathe in and out, and how rapidly you are able to do so. Arterial blood gas analysis is second important test in diagnosing COPD. This test measures how much oxygen and carbon dioxide are present in the blood. A high percentage of carbon dioxide in the blood can be an indication of badly functioning lungs.
The principal methods of treatment are pharmacotherapy and smoking cessation, while pulmonary rehabilitation, long-term oxygen therapy, and surgery may be considered in selected patients. Steroids, inhalers and antibiotics may be prescribed to treat various indications of COPD. Smoking stoppage is the most effective interference in stopping the progression of COPD, as well as increasing survival rate of persons suffering with COPD. Hence, smoking stoppage should be the main priority in the treatment of COPD
Track 07: Lung Transplantation
A lung transplant is a surgical procedure to replace a diseased lung with a healthy lung. It is used to improve the quality of life and prolong the lifespan in people affected with severe or advanced chronic lung cases. The surgery can be for one lung or for both. Lung transplants can be over on people of almost all ages from new born to adults up to age 65.
Track08: Stages & Severity on Lung Diseases
There is no formal organizing system for pulmonary fibrosis. Physicians use different factors, like the ones listed below to describe the disease as mild, moderate, severe or very severe.
Pulmonary Function Test or Lung function Test
Six minute walk test
A high resolution CT scan
Track 09: Lung Cancer: Screening, Diagnosis & Treatment
Lung cancer is a condition that causes cells to divide in the lungs uncontrollably which leads to the growth of tumours that reduce a person's ability to breathe. Symptoms of lung cancer involves appetite loss, changes to a person's voice, such as hoarseness, regular chest infections, such as bronchitis or pneumonia, lingering cough that may start to get worse, shortness of breath, unexplained headaches, weight loss and wheezing.
Early diagnosis of lung cancer: It can be lifesaving because lung cancer cells can travel to other parts of the body before a doctor detects them in the lungs. If metastasis has taken place, it makes treating the disease much more difficult.
Treatment for lung cancer: It is based on its location and stage, as well as the overall health of the individual. Possible treatments include
Radiation therapy and targeted therapy
Track 10: Asthma and Allergy
Asthma is a severe chronic condition that affects the air ways. It involves inflammation that makes it difficult to breath inside the lungs. Asthma symptoms occur when the filling of the airways swell and therefore the muscles around them tighten. Mucus then fills the airways further reducing the amount of air produce an asthma “attack,” the coughing and tightness in your chest region that’s typical of asthma
·Chronic Obstructive Airways Disease
·Asthma diagnosis & Treatment
Allergy develops when a person’s body becomes sensitized to a specific essence or condition in which the immune system reacts abnormally to certain foreign essence. Atopy is the genetic bias to develop the allergic diseases. When atopic people are exposed to allergens they can improves an immune reaction that may leads to allergic inflammation.
Track 11: COPD Pathogenesis
Chronic obstructive pulmonary (COPD) disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Pathologic changes in COPD occur in the generous airways, the small bronchioles, and the lung parenchyma. The pathogenic mechanisms are not clear but are most likely diverse. Increased number of activated polymorph nuclear leukocytes and macrophages release elastases in a manner that cannot be counteracted effectively by antiproteases, emerge in lung desolation
Track 12: COPD and Air Pollution
Chronic Obstructive Pulmonary Disease (COPD) and Asthma are especially vulnerable to the obviously harmful effects of air pollutants. Air pollution can cause the increase of COPD and onset of asthma, increase the respiratory morbidity and mortality.
People especially those with COPD or asthma should be aware of the air quality and take excess measures.
Track 13: Pulmonary Rehabilitation
Pulmonary Rehabilitation is a program designed for people with chronic breathing conditions that limit the quality of life and to increase awareness about chronic lung disease. And also learn to achieve exercise with less shortness of breath. Physiologists and respiratory therapists help to determine a safe exercise routine and learn how to exercise. The program teaches a person to be in charge of breathing instead of breathing being the in charge of person. Pulmonary rehabilitation staff will supervise the exercise sessions. And the amount of time taken by the patient for exercise will be increased in gradually, therefore the level of difficulty will change based on your ability. As the muscles get stronger, the patient will exercise longer with less breathlessness.
Track 14: Cardio Pulmonary Disorders
Cardio Pulmonary Disorders are illustrating as the range of serious disorders that affects the heart and lungs. Cardiovascular disease is represent as any abnormal condition characterised heart or blood vessel dysfunction. Cardiovascular Disease (CVD) contains diseases affecting the Heart and blood vessels.
·Pulmonary artery catheterization
· Respiratory Treatment and Dysrhythmias
Track 15: Respiratory Failure and COPD Complications
Respiratory Failure occurs when lungs fail to do their job passing oxygen into your bloodstream and eliminate carbon dioxide. It is a complication of chronic obstructive pulmonary disease (COPD) and other severe respiratory disorders.
COPD prevents the lungs from working efficiently, which can lead to complications.
·Acute respiratory distress syndrome (ARDS)
Track 16: Respiratory Tract Infections
Respiratory Tract Infections are any infectious diseases of the upper and lower respiratory tract.
Upper respiratory tract infection
Lower respiratory tract infection
Upper Respiratory Tract Infection (sinuses and throat)
The infections are caused by virus. Upper respiratory tract (which starts at sinuses and ends at vocal chords) infection includes the common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis and acute otitis media.
Lower Respiratory Tract Infection (airways and lungs)
Lower respiratory system begins at vocal chords and ends at lungs. Lower respiratory tract infections includes acute bronchitis, bronchiolitis, pneumonia and tracheitis. Lower respiratory tract infections tend to establish and can be severe.
Track 17: Respiratory and sleep Medicine
Sleep Medicine is a multidisciplinary field with contributions by practitioners and researchers from different disciplines. Pulmonary medicine has made important contributions to the field of sleep medicine for the past many years.
Patients suffering from COPD have sleep protests characterized by a longer time to fall asleep, more constant arousals and awakenings in sleep, and generalized insomnia. Sleep disturbance leads to be more severe as the disease advances and substantially reducing the patient’s quality of life.
·Disorders of hypersomnia
·Circadian rhythm disorders
·leep-related movement disorders
Track 18: Self-Management and Prevention of COPD
Self-Management arrangement in COPD includes quitting smoking, improving exercise and physical activity levels, proper nutrition, and medication adherence. It is concentrating on a system for the exacerbation, and enhanced communication between the patient and health care providers make good clinical sense. It is deliberated an integral components of chronic care model of disease management which involves health care organization, community resources, delivery system redesign, and clinical information systems.
It helps the patient to acquire knowledge and skills required to follow the medical therapies. An efficient review of self-management in COPD concluded that it reduces hospital admissions and has no adverse effects.
Prevention of COPD
Primary Prevention: Avoid exposure, Help fight for clean air, never start smoking or quit smoking, reduce your exposure to COPD causing irritants
Secondary Prevention: Vaccination and Physical activity
Track 19: Depression and Anxiety in COPD
Anxiety and depression are common in patients affected by the chronic obstructive pulmonary disease (COPD). The degree of lung function might not describe anxiety and depression. These are difficult to identify and deal with their symptoms often project with those of COPD. Also, increase the risk of re-hospitalization and mortality. Dyspnea and reduced act capacity are the mechanisms that lead to the symptoms of anxiety and depression associated with COPD. Pulmonary rehabilitation develops anxiety and depression in COPD
Track 20: Pediatric Pulmonology & Critical care
Pediatric Pulmonology is a medical speciality that deals with the diagnosis and treatment of diseases involving respiratory tract and it is a combination of both pulmonology and paediatrics. These are specially qualified in pulmonary pediatric diseases and conditions of chest.
Pediatric pulmonology and Critical Care is accomplished to caring for critically ill patients and patients with lung diseases- asthma, pneumonia, wheezing, bronchitis, COPD, cystic fibrosis. The division of pediatric pulmonary and critical care is consisted of a team of outstanding clinicians, scientists, and scholars dedicated to improve the lives of patients with serious lung disease and those who are critically ill.
·Pediatric Pulmonary Medicine
·Pediatric Pulmonary Hypertension
Track 21: Occupational & Environmental lung Disease
Оссuраtiоnаl & Environmental lung diseases аre grоuр оf diseases саused by the inhаlаtiоn оf dust, сhemiсаls оr рrоteins. The severity of the disease is identified with the material inhаled аnd the emphasis оf exроsure.
Some оf the Оссuраtiоnаl Lung diseаses аre Аsthmа, Brоnсhiоlitis Оbliterаns, СОРD, HyрersensitivityРneumоnitis,LungСаnсer,Mesоtheliоmа, Рneumосоniоsis and Environmental lung diseases are саused by Аrseniс, Аsbestоs, BСME, Beryllium, Саdmium, Сhrоmium, Соаl dust, Diesel exhaust, Indium lung, Nickel, Siliса, and Tоbассо smoke, etс.,
Benefits of Participation
- The advantages of the speaker and abstract pages are created in Google on your profile under your name would get worldwide visibility.
- Our comprehensive online advertising attracts 30000+ users and 50000+ views to our Library of Abstracts, which takes researchers and speakers to our conference.
- Meet with hundreds of like-minded experts who are pioneers in COPD 2023 and share ideas.
- All participants in the conference would have a different reason to participate with eminent speakers and renowned keynote speakers in one-to-one meetings.
- A rare opportunity to listen what the world's experts are learning about from the world's most influential researchers in the area of cardiology at our Keynote sessions.
- COPD 2023 intensive Conference schedule, you will acquire experience and expertise in strategic gift preparation that is worth its weight golf, forming an impressive array of recognized professionals.
- Best Poster Award nominations.
- Award for Outstanding young researcher
- Group Registration Advantages.
Benefits of Participation for Speaker
- Access to all Sessions (Keynote, Plenary, Poster, E-Poster)
- Certificate Accreditation from the Organizing Committee
- Abstracts will be published in the conference souvenir and respective international journal
- Each registrant will get 50% abatement on manuscript publication fees
- Access to the attendees email list (post conference)
- Worldwide appreciation of the profile of research
- Obtain credits for professional growth.
- Explore the latest of cutting edge analysis.
- Make long-term bonds at social and networking activities.
- An ability to advertise one page in the distribution of abstract books and flyers that ultimately gets 1 million views and adds great value to your research profile.
- Learn a transition beyond your area of interest to learn more about new subjects and studies away from your core subject of cardiology
- We have distinctive networking, learning and enjoyable integration into a single package.
Benefits of Participation for Delegate
- Professional Development-Improve understanding and knowledge
- Attendance at conferences supports rejuvenates and energizes delegates.
- Your involvement in our conference will help with a new methodology and ideology that can be used to broaden the outcomes of business or industries.
- Opportunities for COPD 2023 researchers and experts in the same field to meet and exchange new ideas through a COPD Conference.
Benefits of Participation for Sponsor
- Exposure to the international environment would increase the possibility of new companies
- Opportunity to demonstrate your company's latest technologies, new products, or service your business to a wide range of international participants.
- Increase business by our conference participants through lead generation.
- It takes a lot of time, effort and drive to create a successful company, so it's always nice to have a network of colleagues and associates to draw energy from individuals who share a common drive and objective.
- Conferences in cardiology provide opportunities for more attention and contemplation that could help you move your company to the next stage.
- Benchmarking main organisation plans
The market value of COPD was approximately $10.9 billion in 2018, growing at a compound annual growth rate (CAGR) of about 5.9%, and is predicted to reach US$19.3 billion in 2028, according to a research analysis by Research and Markets. The COPD market is made up of these, with the US market accounting for around 40% of it and developed regions like Europe and Japan for 18% and 9.2%, respectively. The market for COPD medications has been gradually growing in China in recent years. According to PDB data, the domestic Chinese COPD market was worth RMB 2.2 billion ($324 million) in 2018. Compound annual growth rate was 15.56%. Because of the rising prevalence of COPD around the world, the COPD market has grown quickly, The cause of COPD, however, differs regionally.
In 2016, there were 251 million cases of chronic obstructive pulmonary disease globally, and a mean of 1 person passed away from COPD every 10 seconds, according to the global Burden of Disease Research Report. Furthermore, COPD has a long course and patients frequently require frequent medical checkups, hospitalisation, and long-term care due to acute exacerbations, all of which require significant amounts of medical resources. It has grown to be a complex worldwide illness burden, and scientists, pharmaceutical companies, and investors are paying increasing attention to it.
Finding new treatments for chronic obstructive pulmonary disease is difficult due to a lack of funding for this field of study as well as challenges in conducting clinical trials. However, there are rays of light, such as the ability to reverse steroid resistance and pinpoint certain patient subpopulations.
Past Conference Report
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by